ABSTRAL CONSERVATIVE ESTIMATE = NO FURTHER DILUTION
There will be no further dilution. That is a FACT unless Mark Ahn was blatantly lying.
At the last CC (Oppenheimer, 12/4), Mark Ahn was clear as day that they had already surpassed 5% market share for Abstral sales. If we assume a 500 million dollar market for fentanyl, that would be an annual rate of 20 million dollars. The quarterly rate would be 5 million.
The last published burn rate was 1.25 million/month. We can say 4 million a quarter, again conservatively.
Therefore, we have already, at a BARE MINIMUM dealt with our burn rate and will no longer require further dilution.
Anything greater than 5% is net revenue and the company, independent of neuvax, REAL monitized value.